Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Artielle, QSV Sign cGMP Contract for MS Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Artielle, QSV Sign cGMP Contract for MS Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

QSV Biologics, Ltd. and Artielle ImmunoTherapeutics, Inc. have signed a contract for the process development and cGMP manufacturing of RTL 1000 for multiple sclerosis. QSV will be responsible for technology transfer, process development and cGMP manufacture of Phase II/III trial material. RTL 1000, licensed by Artielle from Oregon Health & Science University, is a Recombinant T cell receptor Ligand (RTL) that can treat a wide range of autoimmune diseases.

Graeme Macaloney Ph.D., PEng, QSV president and chief executive officer said, “The combination of novel class of molecules, experienced management team, and quality investors behind Artielle ensure the best possible opportunity for successfully bringing these much needed autoimmune disease therapies to patients. We are proud to be providing the manufacture of this important MS therapeutic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics